QURE Investigation Notice: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

Core Points - Kessler Topaz Meltzer & Check, LLP is investigating potential violations of federal securities laws on behalf of investors of uniQure N.V. [1] - On November 3, 2025, uniQure announced that the FDA indicated insufficient evidence from its AMT-130 gene therapy studies to support a Biologics License Application (BLA) [2] - Following this announcement, uniQure's stock price dropped over 50%, from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [3] Company Summary - uniQure N.V. is focused on developing gene therapies, specifically for conditions like Huntington's disease [2] - The company is currently facing challenges regarding the regulatory approval process for its investigational therapy AMT-130 [2] Legal and Regulatory Context - The investigation by Kessler Topaz Meltzer & Check, LLP highlights potential legal implications for uniQure related to securities laws [1] - The FDA's feedback on the adequacy of clinical trial data for AMT-130 raises concerns about the company's future regulatory submissions [2]